IL152941A0 - Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same - Google Patents

Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same

Info

Publication number
IL152941A0
IL152941A0 IL15294101A IL15294101A IL152941A0 IL 152941 A0 IL152941 A0 IL 152941A0 IL 15294101 A IL15294101 A IL 15294101A IL 15294101 A IL15294101 A IL 15294101A IL 152941 A0 IL152941 A0 IL 152941A0
Authority
IL
Israel
Prior art keywords
kits
same
pharmaceutical compositions
compositions containing
heterocyclic compounds
Prior art date
Application number
IL15294101A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL152941A0 publication Critical patent/IL152941A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15294101A 2000-06-21 2001-06-21 Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same IL152941A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21321000P 2000-06-21 2000-06-21
PCT/US2001/019793 WO2001097848A2 (en) 2000-06-21 2001-06-21 Vitronectin receptor antagonist pharmaceuticals

Publications (1)

Publication Number Publication Date
IL152941A0 true IL152941A0 (en) 2003-06-24

Family

ID=22794168

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15294101A IL152941A0 (en) 2000-06-21 2001-06-21 Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same

Country Status (12)

Country Link
EP (1) EP1307226B1 (xx)
JP (1) JP2004521066A (xx)
CN (1) CN1582166A (xx)
AT (1) ATE414541T1 (xx)
AU (2) AU7296501A (xx)
BR (1) BR0111880A (xx)
CA (1) CA2412854C (xx)
DE (1) DE60136632D1 (xx)
IL (1) IL152941A0 (xx)
MX (1) MXPA02012750A (xx)
NZ (1) NZ522925A (xx)
WO (1) WO2001097848A2 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2001258095A1 (en) 2000-05-08 2001-11-20 The University Of British Columbia Drug delivery systems for photodynamic therapy
AU2001271435A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1572639A4 (en) 2002-01-24 2006-08-09 Barnes Jewish Hospital IMAGING AGENTS TARGETING INTEGRINS
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
ATE449614T1 (de) * 2003-05-12 2009-12-15 Lantheus Medical Imaging Inc Vitronectin rezeptorantagonisten und ihre verwendung als radiopharmazeutika
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CA3044877A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
SG11202104657RA (en) 2018-11-23 2021-06-29 Bayer Ag Formulation of contrast media and process of preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001527527A (ja) * 1996-11-27 2001-12-25 デュポン ファーマシューティカルズ カンパニー 新規インテグリン受容体拮抗薬
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
CN1356913A (zh) * 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
AU7002501A (en) * 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
CA2413328A1 (en) * 2000-06-21 2001-12-27 Milind Rajopadhye Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
AU2001271435A1 (en) * 2000-06-21 2002-01-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1311301A2 (en) * 2000-07-06 2003-05-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof

Also Published As

Publication number Publication date
CA2412854C (en) 2010-08-17
WO2001097848A2 (en) 2001-12-27
WO2001097848A3 (en) 2003-03-13
BR0111880A (pt) 2006-04-25
DE60136632D1 (de) 2009-01-02
AU7296501A (en) 2002-01-02
NZ522925A (en) 2006-08-31
AU2001272965C1 (en) 2006-06-29
JP2004521066A (ja) 2004-07-15
ATE414541T1 (de) 2008-12-15
CA2412854A1 (en) 2001-12-27
EP1307226B1 (en) 2008-11-19
MXPA02012750A (es) 2004-07-30
AU2001272965B2 (en) 2005-11-17
CN1582166A (zh) 2005-02-16
EP1307226A2 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
WO2001097861A3 (en) Vitronectin receptor antagonist pharmaceuticals
WO2001097860A3 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
WO2000035492A3 (en) Vitronectin receptor antagonist pharmaceuticals
PT828724E (pt) Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2
NZ504482A (en) Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function
DE69514813T2 (de) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
TR199900046T2 (xx) Se�ici siklooksijenaz-2 inhibit�rleri olarak ikameli piridinler.
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
ATE427936T1 (de) Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivitat
EP0954340A4 (en) ASSOCIATED TARGET IMMUNOTHERAPY AGAINST CANCER
IL152941A0 (en) Fused heterocyclic compounds and kits and pharmaceutical compositions containing the same
DE69631975D1 (de) Discodermolide verbindungen und deren pharmazeutische zusammensetzungen zur krebstherapie
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
ATE233754T1 (de) Diphenyl-piperidin derivate
EA200500882A1 (ru) N-арилсульфонил-3-аминоалкоксииндолы
WO2000035887A3 (en) Vitronectin receptor antagonist pharmaceuticals
ATE183192T1 (de) Neue colon-oder ilean-spezifische steroid derivate
TR200103680T2 (tr) IL-8 reseptör antagonistleri.
DK1140203T3 (da) Farmaceutiske præparater som vitronectinreceptorantagonist
TR199801614T2 (xx) Peptit t�revleri
TR199902094T2 (xx) 3-Heteroareil-4(3H)-kinazolinonlar�n atropizomerleri.
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
TR199801915T2 (xx) Benzotiofenler, bunlar� ihtiva eden form�lasyonlar ve y�ntemler.